Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc., has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project. “We are extremely delighted and honored that Mapp Biopharmaceutical, Inc. contracted Avid Bioservices as their CDMO to support the company’s antiviral program. Today, we are all too familiar with viral outbreaks and, as part of the scientific community, we are proud to leverage our expertise to support the prevention and treatment of challenging viruses,” said Timothy Compton, chief commercial officer of Avid. “This agreement with Mapp Biopharmaceutical provides further evidence of the significant momentum that Avid’s business development team continues to generate toward our dual goals of revenue growth and customer base diversification. We are pleased to add Mapp to our growing list of customers. We are eager to get to work so that we can efficiently move toward To keep reading about Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody, Click on the link. Seoul, Korea
http://dlvr.it/RfNVmH

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

AT&T Sells DirecTV Stake To Private Equity Firm TPG

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. (RTTNews) - AT&T Inc. (T) has reached a deal with private equity firm TPG Capital to make its struggling satellite TV provider DirecTV a new standalone company. The deal will establish a new company that will own and operate AT&T's U.S. video business unit consisting of the DirecTV, AT&T TV and U-verse video services. The new company will have an enterprise value of $16.25 billion. The company will be jointly governed by a board with two representatives from each of AT&T and TPG, as well as a fifth seat for the CEO, which at closing will be Bill Morrow, CEO of AT&T's U.S. video unit. Following the close of the transaction, AT&T will own 70% of the common equity and TPG will own 30%. AT&T will receive $7...
Read more

7 lies to stop telling yourself if you want to become mentally stronger

Image
Crystal Cox/Business Insider Amy Morin is a psychotherapist, licensed clinical social worker, mental strength coach, and international bestselling author. She explains that sometimes our own thoughts can hold us back, especially if we tend to dwell on negative events, insecurities, and self-doubt. Morin says it's important to confront thoughts like "I'm not good enough" or "I'm too damaged," and replace them with self-empathy by instead saying "I am worth it" or "I'm a survivor." Visit Business Insider's homepage for more stories. Many of the things you tell yourself aren't true. And there's a good chance you've bought into some unhealthy beliefs over the years. Courtesy of Amy Morin In the therapy world, we call these "cognitive distortions." We all have them. Learning to recognize these lies we tell ourselves and replace them with healthier, more realistic statements is key to building mental str...
Read more